Cases selected for the AskAnzal weekly PMCPA insight newsletter
A hospital doctor said an Imraldi mailing requiring a signature was harassment and an inappropriate marketing practice. Panel…
A senior employeeβs LinkedIn comment praising Strivit D3 (βlicensed, prescribed, kosher and halalβ) was ruled to be public…
Complaint said an Ozempic promotional email implied use in all type 2 diabetes patients because βadultsβ appeared later…
Tevaβs HCP and education websites were ruled promotional in parts. Breaches included missing prominent PI/AE signposting online, missing…
Bayer challenged Janssenβs Erleada promotional video alleging off-licence promotion and misleading/disparaging cross-trial safety comparisons. The PMCPA Panel ruled…
Complaint alleged LinkedIn promotion and breach of an undertaking by AstraZeneca. PMCPA concluded the matter was outwith the…
Daiichi Sankyo facilitated an AF digital diagnosis opinion article on an independent news site, but its involvement was…
Theramexβs LinkedIn βAbout Usβ described its solutions as βinnovative, effective and safeβ. The PMCPA ruled this was misleading…
A GP complained about an allegedly unsolicited promotional email for Actonel Combi. The Panel found the recipient had…
A Times diabetes supplement funded and editorially controlled by Novo Nordisk included trial claims about unapproved liraglutide. The…
One real case. One key lesson. Every week β free.